Current and developing chemotherapy for CLL

Medical Oncology

Volumn 19, Issue SUPPL., 2002, Pages

  Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alemtuzumab; Alkylating agents; B cell; Chronic; Leukemia; Monoclonal antibody Campath 1H; Remission induction; Vincristine

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; EPIRUBICIN; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; MITOXANTRONE; MONOCLONAL ANTIBODY; PREDNISONE; PURINE DERIVATIVE; RITUXIMAB; VINCRISTINE; ALEMTUZUMAB; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; DRUG DERIVATIVE; VIDARABINE;

ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CLINICAL TRIAL; DRUG CONTRAINDICATION; DRUG POTENTIATION; DRUG RESPONSE; HUMAN; NAUSEA; PRACTICE GUIDELINE; PRIORITY JOURNAL; SURVIVAL RATE; TREATMENT OUTCOME; VOMITING; MORTALITY; PATHOLOGY; REVIEW;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS; HUMAN; LEUKEMIA, LYMPHOCYTIC, CHRONIC; SURVIVAL RATE; VIDARABINE; HUMANS;

EID: 0036277109     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1385/MO:19:2S:S11     Document Type: Article

References (58)

1. The annual report to the nation on the status of cancer, 1973-1997, with a special section on colorectal cancer
2. Chronic lymphocytic leukemia: A changing natural history
3. Developing risk-adapted strategies for chronic lymphocytic leukemia
4. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
5. When and how to treat chronic lymphocytic leukemia
6. Chronic lymphocytic leukaemia: Current treatment options
7. Clinical staging of chronic lymphocytic leukemia
8. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis
9. Autoimmune disease and chronic lymphocytic leukemia: Autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia
10. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: Clinical, therapeutic, and prognostic features
11. Chlorambucil in indolent chronic lymphocytic leukemia
12. Is the CHOP regime a good treatment for advanced CLL? Results from two randomized clinical trials
13. Comparison of fludarabine, cyclophosphamide/doxorubicin/prednisone, and cyclophosphamide/doxorubicin/vincristine/prednisone in advanced forms of chronic lymphocytic leukemia: Preliminary results of a controlled clinical trial
14. The experience of the French Cooperative Group in the treatment of CLL
15. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
16. Chronic lymphocytic leukemia
17. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
18. Randomized comparison of fludarabine, CAP and CHOP in 696 previously untreated patients
19. Randomized clinical trial comparing two anthracycline containing regimes (CHOP and CAP) and fludarabine in advanced chronic lymphocytic leukemia
20. Randomized comparison of fludarabine, CAP, and CHOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
21. Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia-updated results of the multicentre study of 378 patients
22. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
23. Infectious and immunosuppressive complications of PA therapy
24. Chronic lymphocytic leukemia
25. Therapy for previously untreated chronic lymphocytic leukemia: A reevaluation
26. Treatment of refractory chronic lymphocytic leukemia with fludarabine phosphate via the group C protocol mechanism of the National Cancer Institute: Five-year follow-up report
27. Fludarabine in resistant or relapsing B-cell chronic lymphocytic leukemia: The Spanish Group experience
28. A loading dose/continuous infusion schedule of fludarabine phosphate in chronic lymphocytic leukemia
29. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment
30. Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia
31. Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy
32. Fludarabine treatment in B-cell chronic lymphocytic leukemia: Response, toxicity and survival analysis in 47 cases
33. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: A Southwest Oncology Group study
34. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia
35. In vitro evaluation of fludarabine in combination with cyclophosphamide and/or mitoxantrone in B-cell chronic lymphocytic leukemia
36. Combined therapy with fludarabine and cyclophosphamide in relapsed/resistant patients with B-cell chronic lymphocytic leukaemia and non-Hodgkin's lymphomas
37. Fludarabine and cyclophosphamide as first therapy for lymphoproliferative disorders: Response rates and toxicity
38. Encouraging response rate to sequential cyclophosphamide (Cy) followed by fludarabine phosphate (FI) in newly diagnosed B-cell chronic lymphocytic leukemia (CLL): A Southwest Oncology Group trial
39. Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies
40. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia
41. Clinical challenges in chronic lymphocytic leukemia
42. Low-dose fludarabine and cyclophosphamide in elderly patients with B-cell chronic lymphocytic leukemia refractory to conventional therapy
43. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma
44. Idarubicin in low-grade non-Hodgkin's lymphomas
45. Treatment of indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial
46. Multicenter phase II study of oral idarubicin in treated and untreated patients with B-chronic lymphocytic leukemia
47. Fludarabine plus doxorubicin in previously treated chronic lymphocytic leukemia
48. Phase I study of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade lymphoma
49. A phase II study of fludarabine (F) and mitoxantrone (N) in the treatment of previously untreated B-cell chronic iymphocytic leukemia
50. Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: A German multicenter phase II study
51. Fludarabine as a modulator of cisplatin activity in human tumour primary cultures and established cell lines
52. Fludarabine triphosphate inhibits nucleotide excision repair of cisplatin-induced DNA adducts in vitro
53. Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: Induction of synergistic cytotoxicity independent of reversal of apoptosis resistance
54. Sequential cis-platinum and fludarabine with or without arabinosyl cytosine in patients failing prior fludarabine therapy for chronic lymphocytic leukemia: A phase II study
55. Combination fludarabine, cyclophosphamide and rituximab for previously treated patients with chronic lymphocytic leukemia (CLL)
56. Combination chemo-antibody therapy with fludarabine (F), cyclophosphamide (C) and rituximab (R) achieves a high CR rate in previously untreated chronic lymphocytic leukemia (CLL)
57. Rituximab added to fludarabine improves response in previously untreated chronic lymphocytic leukemia: Preliminary results from CALGB 9712
58. Campath-1H with fludarabine: A novel, highly active combination in refractory CLL